Vivos Therapeutics Reports FY2023 Revenue Decline, 27% OpEx Reduction, and FDA Clearance for Severe OSA

Vivos Therapeutics, Inc.

Revenue for Q4 2023 was $3.2M and full year $13.8M, down from $4.0M and $16.0M in 2022, due to lower appliance revenue and VIP enrollments.
Operating expenses decreased 27% in FY2023, leading to a 43% reduction in net loss, as cost-cutting initiatives took effect.
In November 2023, Vivos received FDA 510(k) clearance for its CARE oral appliances to treat severe OSA in adults, a first for oral devices.
Signed VIP enrollment contracts increased 38% sequentially in Q4 2023 following the FDA clearance, indicating improved business momentum.
Cash and equivalents were $1.6M at year-end; a warrant exercise in February 2024 generated $4.0M in gross proceeds.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Vivos Therapeutics, Inc. reported financial results for fourth quarter and full year ended December 31, 2023.

Period: fourth quarter and full year ended December 31, 2023
Result: reported results

Exact text from the filing

On March 28, 2024, Vivos Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the fourth quarter and fiscal year ended December 31, 2023.

View on SEC.gov

1349 earnings releases filed in the last 30 days. Browse all earnings releases →

Vivos Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-24-011834

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.